FOR IMMEDIATE RELEASE National Forum for Heart Disease & Stroke Prevention Announces New Chair of Value & Access Initiative WASHINGTON, DC, July 25, 2019 – The National Forum for Heart Disease & Stroke Prevention announced that Michael Cropp, MD, MBA, President & CEO of Independent Health will serve as the Chair of the …
Immediate Past National Forum Board Chair, Dr. Jennifer Robinson, lead author on Updated Guidance from the NLA Identifying Patients in Which PCSK9i Use Provides Reasonable Value
During it's 2019 Scientific Sessions, the National Lipid Association (NLA) released a statement paper, led by Dr. Jennifer Robinson, Immediate Past National Forum Board Chair. The paper provides updated guidance to clinicians with identifying patient groups in which use of PCSK9 monoclonal antibodies (mAbs) provides a reasonable value. Read the …
Celeste Philip Appointed Head of Public Health in Sonoma County
The Sonoma County, California Board of Supervisors approved yesterday the appointment of National Forum Board Member Celeste Philip, MD, MPH, as County Health Official. Dr. Philip, the former Secretary of Health and state Surgeon General in Florida, begins her new role on April 9. “Dr. Philip’s leadership will translate to more opportunities for …
ACC/AHA Release Guidance for Preventing Heart Disease & Stroke
Key recommendations in the 2019 Primary Prevention of Cardiovascular Disease guideline from the American College of Cardiology (ACC) and the American Heart Association (AHA) focus on adopting heart healthy habits, such as a heart healthy eating plan, getting more exercise, avoiding tobacco and managing known risk factors. It is also recommended …
National Forum Statement on Praluent Price Change
The National Forum issued the following statement in response to Sanofi and Regeneron’s announcement that they cut the list price of their LDL (“bad”) cholesterol-lowering treatment, Praluent, to $5,850 annually, a 60 percent reduction from the original list price. Amgen announced a similar price reduction in October 2018 on Repatha. Both Praluent …
The Healthy People 2030 public comment period is now open! Review the proposed objectives, submit comments, or propose your own objective.
The U.S. Department of Health and Human Services (HHS) is soliciting written comments on the proposed objectives for Healthy People 2030. This public comment period will allow comments on the proposed HP2030 objectives and members of the public can also propose their own objectives. Previous public comments on the proposed Healthy People 2030 …
National Forum Statement on Amgen’s Repatha Price Change
The National Forum issued the following statement in response to Amgen's announcement that it cut the price of its cholesterol-lowering drug, Repatha, by 60 percent. Leaders representing patients, providers, public health, payers and pharma/biotech have joined forces through the National Forum Value & Access Initiative to enhance health and …
The National Forum Awards Winners for Exceptional Contributions to Heart Disease and Stroke Prevention
2018 National Forum Awards The National Forum annually recognizes individuals and organizations who have made exceptional contributions to heart disease and stroke prevention during its Annual Meeting. The following individuals and organizations are the 2018 awardees. National Forum Heart Healthy Stroke Free Awards Presented to an individual and …
Losing ground: Heart disease and stroke deaths hit hardest right in the middle
Cardiovascular disease trend impacting 45-64 year olds WASHINGTON — A new report out today from the National Forum for Heart Disease and Stroke Prevention calls attention to a disturbing trend in the overall death rate from cardiovascular disease (CVD) impacting people ages 45-64. While the overall death rate from cardiovascular disease (CVD) has …